Pay in 4 interest-free payments of $5.89 Learn more
Ships within 48 hours · Estimated delivery Sep 23 - Sep 28
They're not the same as FDA-approved drugs
This fee is only billed once per calendar year per client
In 2-year rat carcinogenicity studies referenced in the Increlex label, increased mammary and skin tumor incidence occurred at high IGF-1 exposure
In diabetes management, peptide-based therapies may reduce long-term complications and associated healthcare costs despite higher initial drug expenses
Blood Pressure Medications Potential interference with effectiveness May require dose adjustments Regular BP monitoring essential Always inform your healthcare provider about IGF-1 LR3 use when starting any new medication
US$ 27.82
US$ 27.26
US$ 22.99
US$ 28.05
US$ 24.84
US$ 25.91
US$ 25.06
US$ 28.84
US$ 23.00
US$ 29.15
US$ 26.58
